Le Lézard
Classified in: Health, Covid-19 virus
Subjects: TRD, AVO

Council for Innovation Promotion Urges Biden Admin to Oppose IP Waiver

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Yesterday, the Council for Innovation Promotion (C4IP) and nearly 50 former government officials and intellectual property experts sent a letter to President Biden urging his administration to oppose the World Trade Organization's proposed IP waiver for Covid-19 therapeutics and diagnostics.

Notable letter signatories include former U.S. Secretary of Commerce Gary Locke, Director of the U.S. Patent and Trademark Office Michelle Lee, U.S. Deputy Secretary of Defense John Hamre, Deputy Director General of the UN's World Intellectual Property Organization James Pooley, Director of the National Institute of Standards and Technology Walter G. Copan, and Governor Howard Dean.

"The WTO's proposal to suspend IP rights for certain Covid-19 technologies would jeopardize the development of these critically important technologies and harm the ability to diagnose and treat Covid-19 patients," said Andrei Iancu, C4IP co-chair and former director of the U.S. Patent and Trademark Office. "The proposal would also decrease investment in all other lifesaving American medical R&D and will harm U.S. economic competitiveness. For the United States to maintain its technological edge, the administration should oppose this measure."

In October, the U.S. International Trade Commission published a report on the proposed IP waiver and found no evidence that intellectual property protections impeded access to Covid-19 therapeutics and diagnostics.

"IP rights have played a pivotal role in the record-breaking development of Covid-19 vaccines, tests, and therapies from the outset of the pandemic," said David Kappos, C4IP co-chair and former director of the U.S. Patent and Trademark Office. "Suspending IP protections for these products would make it impossible to duplicate this success going forward and undermine our ability to respond to future global health crises."

The World Trade Organization will likely decide whether to approve the proposed IP waiver for Covid-19 diagnostics and therapeutics in February 2024 at the 13th WTO Ministerial Conference.

"The Council for Innovation Promotion is honored to lead this distinguished group in advocating for the preservation of global IP rights," said Frank Cullen, C4IP executive director. "IP drives creativity and innovation worldwide, and the bipartisan solidarity of this group sends a clear message about the importance of maintaining these safeguards. We hope the Biden administration strongly considers these experts' voices when evaluating the WTO's proposed IP waiver."

About the Council for Innovation Promotion: The Council for Innovation Promotion is a bipartisan coalition dedicated to promoting strong and effective intellectual property rights that drive innovation, boost economic competitiveness, and improve lives everywhere.

Media contact
Morgan Miller
[email protected]

SOURCE Council for Innovation Promotion

These press releases may also interest you

at 07:41
Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has launched its multimodal therapy AI guidance platform for life science research. The novel AI software and scientific results, showing potential to...

at 07:35
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, today announced the acquisition of software innovator SEIN Infotech...

at 07:35
Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently...

at 07:35
Lobe Sciences Ltd. ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months....

at 07:35
CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million. Participants in the round include prior investors comprised of industry...

at 07:35
Strand Therapeutics, the world's first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient has been dosed in their Phase 1, first-in-human trial of STX-001, an...

News published on and distributed by: